FDA approves Lundbeck's new antidepressant Lexapro  

The US Food and Drug Administration approves escitalopram, ready for launch next month

Danish pharmaceutical company H. Lundbeck A/S has announced that the US Food and Drug Administration (FDA) has approved their new SSRI drug Lexapro (escitalopram) for the treatment of major depression. Lundbeck's partner in the USA, Forest Laboratories, expects Lexapro to be available in pharmacies by 5 September 2002 and has increased its salesforce by 40% in anticipation. The new drug protects and extends the market share Lundbeck has already built in the US with its predecessor Celexa (citalopram).


H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2001, the company's revenue was DKK 7.7 billion (USD 1 billion) and the number of employees approx. 4,000.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×